S
Susan F. Leitman
Researcher at National Institutes of Health
Publications - 246
Citations - 21793
Susan F. Leitman is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Transplantation & Leukapheresis. The author has an hindex of 64, co-authored 246 publications receiving 20933 citations. Previous affiliations of Susan F. Leitman include Government of the United States of America & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Steven A. Rosenberg,Michael T. Lotze,Linda M. Muul,Alfred E. Chang,Fred P. Avis,Susan F. Leitman,W. Marston Linehan,Cary N. Robertson,Roberta E. Lee,Joshua T. Rubin,Claudia A. Seipp,Colleen Simpson,Donald E. White +12 more
TL;DR: This immunotherapeutic approach can result in marked tumor regression in some patients for whom no other effective therapy is available at present, and determining its ultimate role in cancer therapy awaits further attempts to increase the therapeutic efficacy of treatment and decrease its toxicity and complexity.
Journal ArticleDOI
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
Steven A. Rosenberg,Michael T. Lotze,Linda M. Muul,Susan F. Leitman,Alfred E. Chang,S. E. Ettinghausen,Yvedt L. Matory,John M. Skibber,Eitan Shiloni,John T. Vetto,Claudia A. Seipp,Colleen Simpson,Cheryl M. Reichert +12 more
TL;DR: Preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokin interleukin-2 to patients with advanced cancer are described, based on animal models in which this regimen mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice.
Journal ArticleDOI
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley,James Chih-Hsin Yang,Richard M. Sherry,Michael S. Hughes,Richard E. Royal,Udai S. Kammula,Paul F. Robbins,Jian Ping Huang,Deborah Citrin,Susan F. Leitman,John R. Wunderlich,Nicholas P. Restifo,Armen A. Thomasian,Stephanie G. Downey,Franz O. Smith,Jacob A. Klapper,Kathleen E. Morton,Carolyn M. Laurencot,Donald E. White,Steven A. Rosenberg +19 more
TL;DR: Host lymphodepletion followed by autologous TIL transfer and IL-2 results in objective response rates of 50% to 70% in patients with metastatic melanoma refractory to standard therapies.
Journal ArticleDOI
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Richard W. Childs,Chernoff A,N. Contentin,E. Bahceci,Schrump D,Susan F. Leitman,Elizabeth J. Read,John F. Tisdale,Cynthia E. Dunbar,Linehan Wm,Neal S. Young,Austin John Barrett +11 more
TL;DR: Nonmyeloablative allogeneic stem-cell transplantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had no response to conventional immunotherapy, consistent with a graft-versus-tumor effect.
Journal ArticleDOI
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.
Toshihiko Tanno,Natarajan V. Bhanu,Patricia A. Oneal,Sung-Ho Goh,Pamela Staker,Y. Terry Lee,John W. Moroney,Christopher H. Reed,Naomi L.C. Luban,Rui-Hong Wang,Thomas E. Eling,Richard W. Childs,Tomas Ganz,Susan F. Leitman,Suthat Fucharoen,Jeffery L. Miller +15 more
TL;DR: It is suggested that GDF15 overexpression arising from an expanded erythroid compartment contributes to iron overload in thalassemia syndromes by inhibiting hepcidin expression.